Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153309 | 0.92 | — | — | |
| SCHEMBL14224578 | 0.84 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL268997 | 0.81 | — | — | |
| SCHEMBL28066303 | 0.79 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL9150965 | 0.78 | — | — | |
| SCHEMBL16074880 | 0.77 | CYP4F2 (0.41) | ALDH1A1 | |
| SCHEMBL16074707 | 0.77 | CYP4F2 (0.41) | ALDH1A1 | |
| SCHEMBL16074799 | 0.77 | CYP4F2 (0.41) | ALDH1A1 | |
| SCHEMBL16074969 | 0.77 | CYP4F2 (0.41) | ALDH1A1 | |
| SCHEMBL16074771 | 0.77 | CYP4F2 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1026155-A1 | VITAMIN D DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-08-09 | — | — | EP | claimed |
| US-5824811-A | 22-Thiavitamin D3 derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1998-10-20 | — | — | US | claimed |
| EP-1219599-B1 | VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2 ALPHA-POSITION | TAKAYAMA HIROAKI (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-7465541-B1 | Vitamin D3-responsive sequences located 5′-upstream of p27/kip 1 gene and methods of screening for pharmaceutical agents using the sequences | TOSHIYUKI SAKAI (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-0870503-B9 | use of vitamin D derivatives for the manufacture of a medicament for treating MALIGNANT TUMOR METASTASIS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2006-06-28 | — | — | EP | disclosed |
| US-20050113349-A1 | 2-Alpha vitamin D derivatives having substituents | HIROAKI TAKAYAMA (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-0870503-B1 | use of vitamin D derivatives for the manufacture of a medicament for treating MALIGNANT TUMOR METASTASIS | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-0947504-B1 | 16-ENE-VITAMIN D DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6566351-B1 | Administering dihydroxyvitamin D3 derivative for inhibiting bone metastasis of malignant tumor in a patient in need of such inhibition and without treating the underlying cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-20 | — | — | US | disclosed |
| US-6555699-B2 | Antitumor and antirheumatic agents, high binding affinity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20020193616-A1 | 16-ENE-VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1026155-A1 | VITAMIN D DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-08-09 | — | — | EP | disclosed |
| CN-1046502-C | 22-thio vitamin D3Derivatives of the same | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1999-11-17 | — | — | CN | disclosed |
| US-5977092-A | Drug for curing/ameliorating concomitant syndrome of tumor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0947504-A1 | 16-ENE-VITAMIN D DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1999-10-06 | — | — | EP | disclosed |
| US-5824811-A | 22-Thiavitamin D3 derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1998-10-20 | — | — | US | disclosed |
| EP-0870503-A1 | MALIGNANT TUMOR METASTASIS INHIBITORS | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-10-14 | — | — | EP | disclosed |
| CN-1148380-A | 22-thiavitamin D3 derivative | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1997-04-23 | — | — | CN | disclosed |
| EP-0764443-A1 | AMELIORANT OR REMEDY FOR PARANEOPLASTIC SYNDROME | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-03-26 | — | — | EP | disclosed |
| EP-0755922-A1 | 22-THIAVITAMIN D 3 DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1997-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193616-A1 | 16-ENE-VITAMIN D DERIVATIVES | VDR, CYP24A1, CYP2R1 | ALDH1A1 685/4885 |
| US-20050113349-A1 | 2-Alpha vitamin D derivatives having substituents | CYP24A1, CYP2R1, VDR | ALDH1A1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.